Listed

Prime Medicine, Inc.

PRMENasdaqCIK 1894562HealthcareFiscal year ends Dec 31

Latest reported revenue, Q4 FY2025$838.0kRevenue, Q4 FY2025, three months to 2025-12-31$838.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figureThree months to Dec 31, 2025, from the 10-K filed Mar 3, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenuenot reported (Revenue not reported)No year-earlier figure to compare
  • Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
  • Operating marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Net marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Diluted EPS−$0.24Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure+41.5% on a year earlier
  • Free cash flow−$41.1mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$41.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001628280-26-053883. Derived: 6-month figure less the 3-month figure.Capital expenditure: $46.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001628280-26-053883. Derived: 6-month figure less the 3-month figure.Report this figure+4.4% on a year earlier

Last eight quarters

Full statements
Revenue$838.0kOperating margin −5800.5%
Diluted EPS−$0.24, Q2 FY2026
Free cash flow−$41.1m, Q2 FY2026
Prime Medicine, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m0.2Revenue, Q3 FY2024, three months to 2024-09-30$209.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure2.2Revenue, Q4 FY2024, three months to 2024-12-31$2.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figure1.5Revenue, Q1 FY2025, three months to 2025-03-31$1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-08, accession 0001628280-25-023486.Report this figure1.1Revenue, Q2 FY2025, three months to 2025-06-30$1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-07, accession 0001628280-25-038619.Report this figure1.2Revenue, Q3 FY2025, three months to 2025-09-30$1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure0.8Revenue, Q4 FY2025, three months to 2025-12-31$838.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)
Operating margin%(25948.3%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$54.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Revenue: $209.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure(2025.7%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$44.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Revenue: $2.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figure(3603.3%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$52.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Revenue: $1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-08, accession 0001628280-25-023486.Report this figure(4787.2%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$53.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Revenue: $1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-07, accession 0001628280-25-038619.Report this figure(4406.0%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$54.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Revenue: $1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure(5800.5%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$48.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Revenue: $838.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)
Net margin%(25128.2%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$52.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Revenue: $209.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure(1936.6%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$42.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Revenue: $2.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figure(3568.8%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$51.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Revenue: $1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-08, accession 0001628280-25-023486.Report this figure(4716.7%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$52.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Revenue: $1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-07, accession 0001628280-25-038619.Report this figure(4129.1%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$50.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Revenue: $1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure(5498.7%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$46.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Revenue: $838.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)
Diluted EPS$ per share(0.44)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figurenot reported (Diluted EPS not reported)(0.40)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.40 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure(0.41)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure(0.32)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.32 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figurenot reported (Diluted EPS not reported)(0.28)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure(0.24)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure
Free cash flow$m(27.2)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$25.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-07, accession 0001628280-25-050422. Derived: 9-month figure less the 6-month figure.Capital expenditure: $1.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-07, accession 0001628280-25-050422. Derived: 9-month figure less the 6-month figure.Report this figure14.5Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $16.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Capital expenditure: $1.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figure(51.3)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$48.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Capital expenditure: $2.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure(43.0)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$41.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001628280-26-053883. Derived: 6-month figure less the 3-month figure.Capital expenditure: $1.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001628280-26-053883. Derived: 6-month figure less the 3-month figure.Report this figure(35.3)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$35.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-07, accession 0001628280-25-050422. Derived: 9-month figure less the 6-month figure.Capital expenditure: $247.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-07, accession 0001628280-25-050422. Derived: 9-month figure less the 6-month figure.Report this figure(37.5)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$37.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Capital expenditure: $290.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figure(42.9)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$42.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Capital expenditure: $214.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure(41.1)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$41.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001628280-26-053883. Derived: 6-month figure less the 3-month figure.Capital expenditure: $46.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001628280-26-053883. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$4.6mOperating margin −4498.1%
Diluted EPS−$1.35, FY2025
Free cash flow−$167.1m, FY2025
Prime Medicine, Inc., key figures for the last five fiscal years
Line itemUnitFY2021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m0.0Revenue, period not labelled, twelve months to 2021-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-09, accession 0001628280-23-007266.Report this figure0.0Revenue, FY2022, twelve months to 2022-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-09, accession 0001628280-23-007266.Report this figure0.0Revenue, FY2023, twelve months to 2023-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-28, accession 0001628280-25-008884.Report this figure3.0Revenue, FY2024, twelve months to 2024-12-31$3.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001628280-26-013569.Report this figure4.6Revenue, FY2025, twelve months to 2025-12-31$4.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001628280-26-013569.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)(6787.4%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$202.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001628280-26-013569.Revenue: $3.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001628280-26-013569.Report this figure(4498.1%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$208.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001628280-26-013569.Revenue: $4.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001628280-26-013569.Report this figure
Net margin%not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)(6566.6%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$195.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001628280-26-013569.Revenue: $3.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001628280-26-013569.Report this figure(4342.4%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$201.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001628280-26-013569.Revenue: $4.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001628280-26-013569.Report this figure
Diluted EPS$ per share(14.19)Diluted EPS, period not labelled, twelve months to 2021-12-31−$14.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-03-09, accession 0001628280-23-007266.Report this figure(4.19)Diluted EPS, FY2022, twelve months to 2022-12-31−$4.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-01, accession 0001628280-24-008116.Report this figure(2.18)Diluted EPS, FY2023, twelve months to 2023-12-31−$2.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-28, accession 0001628280-25-008884.Report this figure(1.65)Diluted EPS, FY2024, twelve months to 2024-12-31−$1.65 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-03, accession 0001628280-26-013569.Report this figure(1.35)Diluted EPS, FY2025, twelve months to 2025-12-31−$1.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-03, accession 0001628280-26-013569.Report this figure
Free cash flow$m(38.2)Free cash flow, period not labelled, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$34.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-09, accession 0001628280-23-007266.Capital expenditure: $4.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-09, accession 0001628280-23-007266.Report this figure(148)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$131.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-01, accession 0001628280-24-008116.Capital expenditure: $16.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-01, accession 0001628280-24-008116.Report this figure(174)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$165.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-28, accession 0001628280-25-008884.Capital expenditure: $8.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-28, accession 0001628280-25-008884.Report this figure(130)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$122.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-03, accession 0001628280-26-013569.Capital expenditure: $7.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-03, accession 0001628280-26-013569.Report this figure(167)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$162.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-03, accession 0001628280-26-013569.Capital expenditure: $4.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-03, accession 0001628280-26-013569.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

By month, by reported value, last 24 monthsPurchases $5.0mSales $0
Prime Medicine, Inc., open-market insider transactions
DateInsiderTransactionSharesReported priceValueFiling
2025-08-01GV 2021 GP, L.L.C.10% owner Purchase1,500,000$3.30$5.0mForm 4

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Prime Medicine, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
Alphabet Inc.2026-06-30$61.1m16,562,498Unchanged
BlackRock, Inc.2026-06-30$35.4m9,602,041Added+1,100,333
ARK Investment Management LLC2026-06-30$30.8m8,348,746Added+2,101,919
STATE STREET CORP2026-06-30$28.0m7,576,460Added+1,231,335
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$16.7m4,522,640Added+48,478
Balyasny Asset Management L.P.2026-06-30$14.6m3,969,082Reduced−154,283
GOLDMAN SACHS GROUP INC2026-06-30$12.7m3,430,518Added+2,460,093
Casdin Capital, LLC2026-06-30$11.7m3,167,175Unchanged
Woodline Partners LP2026-06-30$11.1m3,003,904Added+591
UBS Group AG2026-06-30$10.3m2,794,689Reduced−93,729

Recent filings

All 297 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Prime Medicine, Inc., recent filings
FiledFormWhat it isAccession number
2026-08-0608:03 ET10-QQuarterly reportPeriod 2026-06-300001628280-26-053883
2026-08-0608:02 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001628280-26-053878
2026-07-0808:02 ET8-K8.01 Other events0001628280-26-047590
2026-06-0816:10 ET8-K5.07 Shareholder vote results0001628280-26-041543
2026-05-0708:15 ET10-QQuarterly reportPeriod 2026-03-310001628280-26-031726
2026-05-0708:10 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001628280-26-031719
2026-04-2308:35 ETDEF 14AProxy statementPeriod 2025-12-310001628280-26-026697
2026-04-1608:15 ET8-K5.02 Departure or appointment of officers or directors0001628280-26-025372
2026-03-0308:19 ET10-KAnnual reportPeriod 2025-12-310001628280-26-013569
2026-03-0308:02 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001628280-26-013565

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 3, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1894562
Tickers
PRME
Exchange
Nasdaq
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. Listed shows no prices and gives no investment advice.